A Randomized Double-Blind Controlled Clinical Trail of Venlafaxine Sustained Release Tablets Vs.sustained-Release Capsules in Treatment of Major Depression Disorder

Yiru Fang
2013-01-01
Abstract:AIM To compare the efficiency and safety of venlafaxine sustained-release tablets with sustained-release capsules in treatment of major depression disorder.METHODS The study was a double blinded randomized controlled trial using venlafaxine sustained-release capsules as a positive control.Totally 74 depression patients were enrolled and divided into sustained-release tablets group(n = 38) and sustained-release capsules group(n = 36).All patients were given one tablet(capsule) of venlafaxine(75 mg) or placebo after breakfast in the first 4 days.From the 5 th day,the dosage were increased to 2 tablets(capsules) in both groups and lasted until the end of 8 th week.Hamilton’ s depression scale-17(HAMD-17) and pain visual analogue scale self-rating scale were tested at baseline time and week 1,2,3,4,6,8 of the treatment.The initial appearance of reduction rate of HAMD-17 50% was taken as end point to make survival curves,then the differences of acting times between the two groups were analyzed.RESULTS There were 27 and 26 patients finished the 8-week treatment in venlafaxine ustained-release tablets group and sustained release capsules group,respectively.The response rate and cure rate of the ustained-release tablets group was 71% and 66% respectively,and that of the sustained-release capsules group was 67% and 61% respectively,with no significant differences between the two groups(P 0.05).There were no significant differences in the acting time and the response rate of pain between the two groups(P 0.05).The adverse event rate in the venlafaxine sustained-release tablets group and sustained-release capsules group was 29% and 39% respectively,with no significant difference between the two groups(P 0.05).CONCLUSION The general effectiveness on depression symptoms and accompanied pain symptoms of venlafaxine sustained-release tablets were equal to those of venlafaxine sustained-release capsules,and the same as their safety.
What problem does this paper attempt to address?